Advertisement: Mills and Reeve mid banner
St Johns Innovation Centre
Advertisement: Barclays Corporate
Advertisement: CJBS mid banner
Astrazeneca advertisement
Advertisement: TTP
Advertisement: PwC midbanner
Advertisement: Cambridge Network mid banner
31 January, 2011 - 12:49 By Staff Reporter

Dr Jane Osbourn – MedImmune

Jane joined MedImmune, formerly Cambridge Antibody Technology (CAT), in September 1993. She has many years of experience of antibody engineering and currently leads the Biosuperiors team and the MedImmune Cambridge R & D site. 

She originated several key publications and patents, and also made a significant contribution to the discovery and development of marketed drugs and more than 40 clinical candidates.

Prior to joining CAT, Jane obtained a First Class degree in Natural Sciences (Biochemistry) from the University of Cambridge and completed a PhD at the John Innes Centre for Plant Science Research in Norwich. This was followed by a postdoctoral position at Rutgers University, New Jersey before moving into medical research through a British Heart Foundation Postdoctoral Fellowship at the Department of Medicine at Addenbrooke's Hospital in Cambridge.

Jane is a member of the Board of the BioIndustry Association, a member of the Board of Babraham Bioscience Technologies and a member of the UK Medical Research Council Industry Grant Award Assessment Panel.

Newsletter Subscription

Stay informed of the latest news and features